Literature DB >> 26566785

High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence.

A S von Krogh1,2, P Quist-Paulsen1,2, A Waage1,2, Ø O Langseth1, K Thorstensen3, R Brudevold4, G E Tjønnfjord5,6, C R Largiadèr7, B Lämmle8,9, J A Kremer Hovinga8,10.   

Abstract

UNLABELLED: Essentials The population prevalence of hereditary thrombotic thrombocytopenic purpura (TTP) is unknown. We studied the prevalence of hereditary TTP and population frequencies of two ADAMTS-13 mutations. A high frequency of hereditary TTP related to ADAMTS-13 mutation c.4143_4144dupA was found. Vicinity of ABO blood group and ADAMTS-13 loci may facilitate screening of ADAMTS-13 mutations.
SUMMARY: Background Hereditary thrombotic thrombocytopenic purpura (TTP) caused by ADAMTS-13 mutations is a rare, but serious condition. The prevalence is unknown, but it seems to be high in Norway. Objectives To identify all patients with hereditary TTP in central Norway and to investigate the prevalence of hereditary TTP and the population frequencies of two common ADAMTS-13 mutations. Patients/Methods Patients were identified in a cross-sectional study within the Central Norway Health Region by means of three different search strategies. Frequencies of ADAMTS-13 mutations, c.4143_4144dupA and c.3178 C>T (p.R1060W), were investigated in a population-based cohort (500 alleles) and in healthy blood donors (2104 alleles) by taking advantage of the close neighborhood of the ADAMTS-13 and ABO blood group gene loci. The observed prevalence of hereditary TTP was compared with the rates of ADAMTS-13 mutation carriers in different geographical regions. Results We identified 11 families with hereditary TTP in central Norway during the 10-year study period. The prevalence of hereditary TTP in central Norway was 16.7 × 10(-6) persons. The most prevalent mutation was c.4143_4144dupA, accounting for two-thirds of disease causing alleles among patients and having an allelic frequency of 0.33% in the central, 0.10% in the western, and 0.04% in the southeastern Norwegian population. The allelic frequency of c.3178 C>T (p.R1060W) in the population was even higher (0.3-1%), but this mutation was infrequent among patients, with no homozygous cases. Conclusions We found a high prevalence of hereditary TTP in central Norway and an apparently different penetrance of ADAMTS-13 mutations.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  ADAMTS-13 protein, human; Upshaw-Schulman syndrome; congenital thrombotic thrombocytopenic purpura; mutation; prevalence study

Mesh:

Substances:

Year:  2016        PMID: 26566785     DOI: 10.1111/jth.13186

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Hereditary thrombotic thrombocytopenic purpura.

Authors:  Marie Scully
Journal:  Haematologica       Date:  2019-10       Impact factor: 9.941

2.  The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017.

Authors:  Hendrika A van Dorland; Magnus Mansouri Taleghani; Kazuya Sakai; Kenneth D Friedman; James N George; Ingrid Hrachovinova; Paul N Knöbl; Anne Sophie von Krogh; Reinhard Schneppenheim; Isabella Aebi-Huber; Lukas Bütikofer; Carlo R Largiadèr; Zuzana Cermakova; Koichi Kokame; Toshiyuki Miyata; Hideo Yagi; Deirdra R Terrell; Sara K Vesely; Masanori Matsumoto; Bernhard Lämmle; Yoshihiro Fujimura; Johanna A Kremer Hovinga
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

3.  The global carrier frequency and genetic prevalence of Upshaw-Schulman syndrome.

Authors:  Ting Zhao; Shanghua Fan; Liu Sun
Journal:  BMC Genom Data       Date:  2021-11-17

4.  Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura.

Authors:  Azra Borogovac; Jessica A Reese; Samiksha Gupta; James N George
Journal:  Blood Adv       Date:  2022-02-08

Review 5.  TTP: From empiricism for an enigmatic disease to targeted molecular therapies.

Authors:  Nuno A G Graça; Bérangère S Joly; Jan Voorberg; Karen Vanhoorelbeke; Nicolas Béranger; Agnès Veyradier; Paul Coppo
Journal:  Br J Haematol       Date:  2022-02-10       Impact factor: 8.615

6.  Early indicators of neonatal-onset hereditary thrombotic thrombocytopenia purpura.

Authors:  Jing Liu; Yuelun Zhang; Zhuo Li; Zhenghong Li; Lejia Zhang; Shan Jian; Changyan Wang; Yuqing Song; Zichao Lv; Xiaoyan Tang; Lijuan Gou; Juan Xiao
Journal:  Res Pract Thromb Haemost       Date:  2022-10-13

7.  Novel therapies in thrombotic thrombocytopenic purpura.

Authors:  Camila Masias; Spero R Cataland
Journal:  Res Pract Thromb Haemost       Date:  2017-12-18

8.  Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

Authors:  Teresa Fidalgo; Patrícia Martinho; Catarina S Pinto; Ana C Oliveira; Ramon Salvado; Nina Borràs; Margarida Coucelo; Licínio Manco; Tabita Maia; M João Mendes; Rafael Del Orbe Barreto; Irene Corrales; Francisco Vidal; M Letícia Ribeiro
Journal:  Res Pract Thromb Haemost       Date:  2017-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.